Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study
Source : https://www.sciencedirect.com/science/article/pii/S1389945723002666?via=ihub
To examine the effects of lemborexant (LEM) 5 mg (LEM5) or LEM 10 mg (LEM10) following extended placebo treatment. This post-hoc analysis used subject...
Conclusions: These data suggest that even when insomnia symptoms have improved over time with placebo treatment, additional and sustained clinical gains in sleep outcomes are possible with active treatment using lemborexant.
Insomnia in neurological disorders: Prevalence, mechanisms, impact and treatment approaches
Source : https://www.sciencedirect.com/science/article/abs/pii/S0035378723010056?via=ihub
Insomnia is more prevalent in neurological disorders compared to the general population, with rates ranging from 11 to 74.2% in neurodegenerative diso...
Conclusions/Relevance: In neurological disorders, insomnia has a profound impact on daytime functioning, making its management crucial. Effective treatment can result in improved outcomes, and additional research is necessary to investigate alternative therapeutic options and enhance patient care.
Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement
Source : https://www.sciencedirect.com/science/article/abs/pii/S0028390823002757?via=ihub
Chronic opioid use disturbs circadian rhythm and sleep, encouraging opioid use and relapse. The orexin (OX) system is recruited by opioids and regulat...
Conclusions/Relevance: Dual OX receptor antagonists (DORAs), developed for insomnia treatment, may relieve withdrawal-associated sleep disturbances. This study investigated whether DORA-12, a recently developed DORA, reduces physiological activity disturbances during oxycodone abstinence and consequently prevents oxycodone-seeking behavior.
Developments in Major Depressive Disorder Therapy
Source : https://www.psychiatrist.com/jcp/depression/developments-in-major-depressive-disorder-therapy/
Among the greatest unmet needs in MDD is for effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, alternatives show...
Conclusions/Relevance: After nearly 50 years of legal injunctions against their use, psychedelic drugs have attracted interest among researchers seeking alternative antidepressants. Psilocybin, derived from mushrooms, remains under investigation for its benefits in treatment-resistant depression.
Poor sleep and insomnia, sleep disordered breathing, methodology, sleep and neurology, and much more! - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37596846/
Poor sleep and insomnia, sleep disordered breathing, methodology, sleep and neurology, and much more!
Relevance: This issue covers a broad variety of topics from sleep research and sleep medicine. Starting with poor sleep, insomnia, and mental health; there are a few articles on sleep disordered breathing; followed by articles on methodology, sleep in neurology, about the pharmacology of sleep, sleep homeostasis, and much more. As always, I...